Discover
Let's Talk Risk! Podcast
Let's Talk Risk! Podcast
Author: Where MedTech professionals gain clarity and confidence to navigate complex decisions.
Subscribed: 8Played: 193Subscribe
Share
© Naveen Agarwal, Ph.D.
Description
Let’s Talk Risk! brings together MedTech leaders and practitioners for thoughtful conversations on the challenges that shape risk, quality, innovation, and leadership. With 150+ episodes and more than 30K downloads, it helps professionals gain the clarity and confidence to lead through complex decisions.
naveenagarwalphd.substack.com
naveenagarwalphd.substack.com
192 Episodes
Reverse
Summary“Be guided by your own values and facts. That’s important. That will keep you centered”Quality and regulatory leadership in MedTech is about much more than ensuring compliance. Senior leaders must navigate changing regulatory expectations, protect patient safety, support business continuity, and make difficult decisions when priorities collide.In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Ojas Zatakia, a global quality and regulatory executive with more than 23 years of experience across the United States, Europe, the Middle East, and Asia Pacific.Drawing on his international leadership experience, Ojas shares how to manage regulatory disagreements constructively, communicate difficult messages to business leaders, and turn compliance challenges into opportunities for better decisions.Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters00:00 The challenges of senior QA/RA leadership01:34 Ojas’s leadership journey and lessons from global experience03:20 Regulatory differences across international markets06:18 Building constructive relationships with regulatory authorities09:42 Conflicting product classifications and market-access disruption15:45 Managing regulatory uncertainty and business expectations18:36 Balancing compliance, commercial priorities, and patient access20:52 Career growth, AI, and future leadership capabilities26:10 Final leadership lessons: Curiosity, perspective, values, and factsIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:LTR: What We Will Need to Lead in the Age of AI.LTR: Using AI as a Thinking Partner in Product Development.LTR: Collaboration That Drives Innovation Not Delays.Key Takeaways* Global regulatory perspectives: How regional regulatory systems differ while sharing a common commitment to patient and consumer safety.* Working with regulatory authorities: Why listening, understanding different interpretations, and avoiding defensiveness are essential leadership skills.* Navigating regulatory uncertainty: A real-world example of conflicting product classifications, interrupted market access, and the challenges of finding a path forward.* Balancing compliance and business priorities: How early communication helps business leaders understand regulatory risks, prepare alternatives, and avoid unwelcome surprises.* Understanding competing risks: Why regulatory decisions must also consider patient access, supply continuity, and unintended consequences.* Developing future QA/RA leaders: The importance of curiosity, cross-functional understanding, sound judgment, and embracing new technologies such as AI.KeywordsMedTech Leadership, Quality and Regulatory Affairs, Regulatory Risk Management, QA/RA Leadership, Global Regulatory Compliance, Regulatory Strategy, Medical Device Market Access, Patient Safety, Business Continuity, Quality LeadershipAbout Ojas ZatakiaOjas Zatakia is a global quality and regulatory compliance executive with more than 23 years of experience spanning medical devices, pharmaceuticals, and consumer health.Ojas has held senior quality and regulatory leadership roles at Getinge, Philips, including responsibility for global quality operations and regional leadership across Asia Pacific, the Middle East, and Turkey. His experience includes QMS transformation, regulatory remediation, international market access, and leading complex quality organizations through operational change.Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
Summary“First you have to understand the technology, what the technology does, what it's capable of, and you have to understand its limitations.”Artificial intelligence is rapidly changing how medical device companies operate. From complaint handling and nonconformance analysis to CAPA management and technical documentation, the opportunities for efficiency are substantial. But how do we ensure these new capabilities deliver reliable results without introducing unacceptable risks?In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Terry Irwin, Senior Distinguished Engineer at Edwards Lifesciences, about the practical realities of implementing AI within medical device quality management systems.We explore why understanding AI’s capabilities and limitations must come before deployment, how risk-based decisions can guide validation and human oversight, and why quality professionals have an opportunity to lead this transformation.Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters00:00 AI’s expanding role in MedTech quality02:08 Understanding AI capabilities and limitations06:04 Risk-based validation and implementation decisions08:46 Complaint triage, nonconformance analysis, and CAPA13:38 Building a risk-based decision framework17:52 AI literacy, new skills, and opportunities21:16 ChatGPT, Copilot, Gemini, and enterprise adoption strategies25:51 Understanding AI and leading the future of MedTech qualityIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:LTR: AI-Based Virtual Audits.LTR: Building a MedTech Career in the Age of AI. LTR: LTR Risk Coach - AI-Powered Decision Support Tool.Key Takeaways* Beyond the AI hype: Why organizations must understand what AI can—and cannot—reliably do before introducing it into regulated processes.* AI in quality operations: Opportunities to improve complaint triage, nonconformance trending, CAPA analysis, and technical documentation.* Risk-based validation: How a structured decision-tree approach can help determine when AI systems require validation, verification, or human review.* The reliability challenge: Why evaluating AI performance requires understanding data completeness, output accuracy, and the consequences of incorrect decisions.* Human oversight and accountability: The importance of reviewing AI-generated information, particularly when it becomes part of auditable quality records.* A new leadership opportunity: Why AI literacy, software knowledge, and risk management expertise are becoming increasingly valuable skills for quality professionals.KeywordsArtificial Intelligence, MedTech, Quality Management Systems, AI Validation, Risk-Based Decision Making, Human Oversight, Complaint Management, CAPA, AI Governance, Quality LeadershipAbout Terry IrwinTerry Irwin is a Senior Distinguished Engineer at Edwards Lifesciences, with more than 25 years of experience in medical device quality, engineering, and regulatory compliance.His career spans leadership and technical roles at Edwards Lifesciences, Nuvaira, Boston Scientific, and CIVCO Medical Solutions, with extensive experience in design controls, risk management, quality systems, software validation, and product development.Terry currently serves in a quality leadership role supporting AI implementation, bringing together his background in software technology and medical device quality management to help guide responsible adoption.Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
Software velocity is not simply a development challenge. It is becoming an enterprise capability.Software is increasingly driving differentiation, recurring revenue, and customer value in MedTech. But many organizations are still trying to develop and release software through operating models designed for long-cycle hardware.The result is a growing mismatch: agile software teams operating inside rigid funding models, sequential quality processes, and late-stage regulatory gates.This Executive Brief examines what it takes to close that gap—drawing on McKinsey’s analysis of the future of Software as a Medical Device (SaMD).Key highlights covered in the audio brief:* The hardware operating model does not translate cleanly to SaMD. Long development cycles, fixed requirements, and late-stage validation can undermine the speed and iterative advantage that make software valuable.* “Shift left” changes the role of Quality and Regulatory. Design controls, risk management, documentation, and compliance activities move into the development workflow rather than being performed primarily at the end.* Agile quality can create measurable capacity. The report cites substantial reductions in testing, administrative effort, and change-control cycle time—potentially releasing additional developer capacity without simply adding headcount.* Agentic AI could become part of the quality infrastructure. Specialized agents may assist with translating requirements, drafting documentation, identifying potential risks, and maintaining traceability across rapidly changing software systems.* AI remains an augmentation strategy—not an autonomous compliance function. Human quality, regulatory, clinical, and engineering experts must continue to review, validate, and make the consequential decisions.* Funding models may need to change as much as development models. Software portfolios benefit from continuous business-case review and resource allocation based on market feedback and development velocity rather than rigid multi-year investment plans.* The hardest transformation may be cultural. Embedding Quality inside agile product teams requires changes in incentives, accountability, leadership behavior, and the traditional relationship between engineering and compliance functions.Executive takeawayScaling Software as a Medical Device requires more than faster development. It demands an operating model that integrates quality and risk management into agile workflows, uses AI to reduce compliance burdens, and supports continuous investment decisions.The competitive advantage will belong to organizations that can deliver regulated software faster without compromising safety or compliance.KeywordsSoftware as a Medical Device (SaMD), MedTech, Agile Quality, Shift Left, Agentic AI, Design Controls, Risk Management, Regulatory Strategy, Software Lifecycle, Digital Transformation🎧Listen to the Executive Brief for a closer look at how shift-left quality, agile operating models, and emerging agentic AI capabilities could reshape the economics and execution of Software as a Medical Device.Thanks for reading Let's Talk Risk!. If you liked this post, share with others.Note:The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:* McKinsey & Company (2026). The future of delivering software as a medical device. McKinsey’s Life Sciences Practice. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
Summary“At the end of the day, this business of getting a job, keeping a job, getting promoted is human to human.”The MedTech job market has changed.More candidates are competing for fewer well-matched opportunities, applying has become easier at scale, and artificial intelligence is beginning to reshape both how people work and how companies hire.So how do professionals stand out?In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Mitch Robbins, Founder and Managing Director of The Anthony Michael Group, about what he is seeing across the MedTech talent market and what professionals at every career stage can do to prepare.Mitch argues that simply submitting more applications is not enough. Candidates need to understand the problems organizations are trying to solve, communicate the outcomes they have delivered, build relationships before they need them, and become more proactive in how they manage their careers.They also discuss where AI may affect entry-level work, why AI-generated resumes can actually make candidates look more alike, how professionals should describe contributions to cross-functional projects, and what students and mid-career professionals can do now to build long-term career resilience.Listen to the full 25-minute podcast or jump to a section of interest listed below. Chapters00:00 – The Changing MedTech Career Landscape02:42 – How AI Is Reshaping Jobs and Hiring05:04 – Why Proactive Job Searching Still Matters08:02 – Resumes: Differentiate Through Outcomes, Not Responsibilities09:16 – Positioning Yourself as a Consultant or Solution Provider13:36 – Showing Your Individual Contribution Honestly16:47 – Career Advice for Students and Mid-Career Professionals24:02 – AI, Career Resilience, and the Importance of Human ConnectionIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:LTR: Power up your career with mentoring.LTR: Lead with empathy to grow your Quality career.LTR: LTR Risk Coach - AI-Powered Decision Support Tool.Key Takeaways* Be proactive. Applying is not enough; build direct relationships and get in front of the people making hiring decisions.* Lead with outcomes. Show what improved because of your work, not just the responsibilities you held.* Be precise about your contribution. In cross-functional work, clearly explain what you personally contributed without overstating ownership.* Build your network before you need it. Visibility and relationship equity are much more valuable when developed consistently over time.* Know the problems your audience is trying to solve. Whether you are a student, consultant, or experienced professional, relevance comes from understanding where the need is.* Learn to use AI productively. AI will keep changing work, but human connection, judgment, and demonstrated value remain critical.KeywordsMedTech careers, AI and jobs, medical device recruiting, job search strategy, resume strategy, career development, professional networking, QA/RA careers, talent acquisition, career resilienceAbout Mitch RobbinsMitch Robbins is the Founder and Managing Director of The Anthony Michael Group, an executive search firm serving MedTech, Life Sciences, EMS, CDMO, and CMO organizations.His team’s work spans critical talent needs across Regulatory Affairs, Quality Systems and Compliance, Engineering, Operations and Technical Leadership, Market Access, Reimbursement, and Business Development.Mitch has worked in executive recruiting since 2008 and previously held senior search roles within healthcare recruiting. He is also the host of The Med-Tech Talent Lab podcast.He holds a bachelor’s degree in Psychology and Business from the University of Wisconsin–Madison.Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
PCCPs can turn regulatory cycle time into a competitive advantage, but only if the evidence needed to support future change is funded in advance.Predetermined Change Control Plans (PCCP) are often discussed as a regulatory mechanism for managing future device modifications—particularly for AI-enabled medical devices.But their strategic significance goes considerably further.A well-designed PCCP allows a manufacturer to establish in advance what may change, how those changes will be evaluated, and what evidence will be required before implementation. That can fundamentally change how regulatory, R&D, clinical, and financial planning interact across the product lifecycle.Key highlights covered in the audio brief:* A PCCP pre-authorizes a pathway—not unlimited change. The flexibility remains bounded by the device’s intended use, technological characteristics, safety profile, and the specific modifications included in the authorized plan. * The Modification Protocol is the operational engine. Verification methods, performance criteria, statistical thresholds, data requirements, and implementation procedures must be established before future modifications are made. * Risk has to be evaluated across modifications, not modification-by-modification. The Impact Assessment must consider how planned changes may interact and whether their cumulative effects could alter device safety or performance. * Modularity can reduce regulatory exposure. Structuring proposed modifications and their protocols independently can help prevent a concern with one proposed change from jeopardizing the broader PCCP strategy. * Evidence becomes a capital-planning issue. Having the technical ability to make an update does not mean the company has the independent clinical evidence needed to validate it. Data acquisition, validation studies, blinding, statistical analysis, and other evidence requirements may need to be funded years ahead of deployment.* The product roadmap and evidence roadmap become inseparable. Under this model, companies can only realistically pre-authorize changes they will later have the resources and data to validate. Clinical evidence therefore becomes part of innovation planning rather than something assembled after development. Executive takeawayA PCCP is not simply a faster regulatory pathway. It is an upfront agreement on what may change, how those changes will be validated, and what evidence and risk controls must be in place. Done well, it aligns product, regulatory, clinical, risk, and financial planning—and can turn regulatory cycle time into a competitive advantage.KeywordsPCCP, Predetermined Change Control Plan, FDA, Regulatory Strategy, Medical Device Software, AI/ML Medical Devices, Change Control, Clinical Evidence, Risk Management, Product Lifecycle🎧Listen to the Executive Brief for a closer look at FDA’s expectations for toxicological data, and why extraction design, analytical sensitivity, device variability, and laboratory controls can determine whether a biological safety assessment is truly defensible.Thanks for reading Let's Talk Risk!. If you liked this post, share with others.Note:The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:* FDA (2025). Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions: Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH).* FDA (2026). 510(k) Premarket Notification Summary: EchoPAC Software Only / EchoPAC Plug-in (v211) (K261623). U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH).* FDA (2026). Predetermined Change Control Plans. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH).* Ford, C. (2026). ECG-MR's Clearance Shows the Value and Boundaries of a PCCP. Zaliance Medical Solutions.* Giese, J. D. (2026). PCCPs: Best Practices, FAQs, and Examples. Innolitics. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe




